ASX heavyweights juggle downgrades and dented valuations as regulatory and sector shocks bite

Recent broker downgrades across major ASX companies reflect a cautious investor stance driven by sector-specific challenges and valuation recalibrations. South32, for instance, saw Morgans downgrade its rating from Accumulate to Hold and cut the price target to $4.50 following the aluminium business sale, which was valued significantly below consensus estimates at US$5.6 billion upfront versus expected US$8.8-9.2 billion, signaling a leaner but less valuable company. Similarly, PEXA Group faced a sharp downgrade to Hold with a price target slashed from $14.23 to $9.35 after a regulatory draft proposed a 20% fee reduction, potentially slicing $70 million from annual revenue, underscoring regulatory risks weighing on growth prospects.

Despite some setbacks, brokers maintain nuanced views balancing risks and growth potential. Morgans kept a Buy rating on ResMed even as shares de-rated to roughly 16 times forward earnings—the lowest since the post-GFC era—citing sustained earnings growth and limited evidence of demand deterioration despite competitive pressures from GLP-1 therapies. Meanwhile, Objective Corporation’s rating stayed at Buy despite a 22-23% cut in NPAT forecasts due to the loss of a long-term government contract, reflecting confidence in its broader business resilience.

Ord Minnett and Morgans reveal a mixed outlook for industrial and financial services firms amid operational uncertainties and strategic shifts. Worley’s downgrade to Hold with a reduced price target around $12.70 stems from concerns over near-term earnings volatility and a riskier business mix increasingly weighted toward EPC projects, compounded by softer energy sector capex expectations that led Morgans to cut EBITA forecasts by up to 9%. Judo Capital also faced a Hold downgrade with a steep price target cut to $1.60 due to deteriorating loan exposures and shaken management credibility, highlighting investor wariness in credit-sensitive sectors.

Conversely, some companies retain broker confidence despite headwinds, reflecting strategic resilience and growth prospects. Ord Minnett’s Buy rating on CAR Group, supported by an expected 9-11% net profit growth in FY27 even after currency impacts, signals optimism about temporary macroeconomic pressures. Morgans’ Accumulate initiation on Qantas with an $11.50 target underscores faith in the airline’s balance sheet strength and long-term growth drivers like fleet renewal and Project Sunrise, despite near-term fuel cost and economic softness challenges.

PEXA is grappling with significant sector-specific regulatory and contract challenges that are reshaping its earnings outlook. The loss of a major government contract with the Australian Department of Defence has already led to a forecasted 22-23% NPAT reduction in FY27-28, while the NSW pricing regulator's proposed 20% fee cut threatens to slash annual revenue by approximately $70 million. Morgans highlighted the abrupt application of this fee cut as particularly disappointing, underscoring the uncertainty clouding PEXA’s future profit profile.

ResMed is navigating a complex landscape marked by sector-wide healthcare de-rating and emerging competitive threats, despite robust earnings growth and stable demand. Its shares have fallen to around 16x forward earnings—the lowest since the post-GFC period—due to factors like GLP-1 therapies, Apnimed’s oral OSA therapy Phase III data, and Philips’ anticipated re-entry into the US PAP market in 2027. Strategically, ResMed is streamlining its portfolio by divesting the structurally challenged MatrixCare business for $490 million, a move praised by Macquarie for improving growth prospects and aligning with its 2030 focus on high-growth sleep and connected healthcare segments. The company plans to return much of the proceeds to shareholders via an accelerated share repurchase, mitigating earnings dilution from recent transactions.

South32’s decision to divest its aluminium business for US$5.6 billion—significantly below consensus valuations of US$8.8-9.2 billion—reflects a strategic effort to simplify its portfolio amid shifting market valuations. While this move streamlines operations, it has prompted broker downgrades and a reduced price target, illustrating the trade-offs companies face when recalibrating portfolios in response to sector-specific pressures.

Worley is contending with sector headwinds including escalating Middle East operational costs and adverse foreign exchange impacts, which have led to an 8-9% reduction in EBITA forecasts and a cautious hold rating. The company’s FY26 Middle East cost impost doubled to $60 million EBITA, while FX effects accounted for a $50 million hit in the second half, underscoring the persistent challenges in managing international project economics within the engineering services sector.

Investor sentiment across the ASX 200 reveals a cautiously optimistic landscape where brokers identify compelling buying opportunities despite ongoing market volatility and sector-specific headwinds. Experts like Jonathon Higgins from United Capital Partners highlight Zip’s potential 50% upside amid scarce sustainable earnings momentum, while Market Partners praise QBE’s position as a leading AI-driven cost-reduction story with shares at 15-year highs, underscoring pockets of robust earnings momentum and attractive valuations in financials. This nuanced optimism reflects a market balancing macro risks with selective confidence in turnaround stories and structural growth plays.

Healthcare stocks such as ResMed and CSL epitomize the mixed but evolving investor sentiment marked by recent price volatility and sector-specific uncertainties. While ResMed shares have declined over 20% in the past year, brokers like Blake Halligan and Morgans maintain buy ratings, citing the company’s leadership in sleep apnoea devices, resilient clinical positioning, and defensive qualities that underpin long-term growth potential despite near-term concerns about GLP-1 drugs possibly reducing demand. The recent rebounds—CSL up 34% and ResMed up 13% over the past month—signal tentative recovery, yet analysts caution that sustained sentiment improvement may take several quarters as investors await clearer earnings evidence.

Brokers emphasize patience and strategic positioning amid the current market environment, encouraging investors to focus on companies with underappreciated growth avenues and resilient fundamentals. Morgans’ buy recommendation on Flight Centre, despite a cautious outlook on recovery timing, and Ord Minnett’s bullish stance on Sigma Healthcare’s UK expansion exemplify this theme, highlighting the value of innovation and market diversification. Similarly, Bell Potter’s positive view on Netwealth Group, with a 20% upside target driven by strong quarterly flows, reflects confidence in selective growth stories that can weather broader volatility.

Despite some downward revisions in price targets, brokers broadly maintain a positive outlook on key ASX 200 shares across mining, healthcare, and energy sectors, viewing recent share price softness as attractive entry points for long-term capital appreciation. Morgan Stanley’s reiterated buy ratings on Telstra, South32, BHP, and Paladin Energy—with expected FY27 gains between 6% and 18%—alongside Citi’s bullish stance on deeply discounted WiseTech Global and Pro Medicus, underscore confidence in sector-specific growth prospects. Macquarie’s 57% upside call on Liontown lithium mining further reinforces the market’s focus on strategic resource plays amid evolving economic conditions.